Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression - PubMed (original) (raw)
doi: 10.1038/sj.ki.5002311. Epub 2007 Apr 25.
Affiliations
- PMID: 17457371
- DOI: 10.1038/sj.ki.5002311
Free article
Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression
N Eto et al. Kidney Int. 2007 Aug.
Free article
Abstract
Podocyte injury is a significant contributor to proteinuria and glomerulosclerosis. Recent studies have shown a renoprotective effect of erythropoietin (EPO) during ischemic kidney disease. In this study, we examine mechanisms by which a long acting recombinant EPO analog, darbepoetin, may confer renoprotection in the puromycin aminonucleoside-induced model of nephrotic syndrome. Darbepoetin decreased the proteinuria of rats treated with puromycin. This protective effect was correlated with the immunohistochemical disappearance of the podocyte injury markers desmin and the immune costimulator molecule B7.1 with the reappearance of nephrin expression in the slit diaphragm. Podocyte foot process retraction and effacement along with actin filament rearrangement, determined by electron microscopy, were all reversed by darbepoetin treatment. The protective effects were confirmed in puromycin-induced nephrotic rats that had been hemodiluted to normal hematocrit levels. Furthermore, puromycin treatment of rat podocytes in culture caused actin cytoskeletal reorganization along with deranged nephrin distribution. All these effects in vitro were reversed by darbepoetin. Our study demonstrates that darbepoetin treatment ameliorates podocyte injury and decreases proteinuria by a direct effect on podocytes. This may be accomplished by maintenance of the actin cytoskeleton and nephrin expression.
Similar articles
- Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo.
Logar CM, Brinkkoetter PT, Krofft RD, Pippin JW, Shankland SJ. Logar CM, et al. Kidney Int. 2007 Aug;72(4):489-98. doi: 10.1038/sj.ki.5002362. Epub 2007 Jun 6. Kidney Int. 2007. PMID: 17554257 - Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro.
Zheng CX, Chen ZH, Zeng CH, Qin WS, Li LS, Liu ZH. Zheng CX, et al. Kidney Int. 2008 Sep;74(5):596-612. doi: 10.1038/ki.2008.203. Epub 2008 May 28. Kidney Int. 2008. PMID: 18509322 - Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome.
Aizawa K, Takeda S, Tashiro Y, Yorozu K, Hirata M, Kanada H, Moriguchi Y, Endo K. Aizawa K, et al. Am J Nephrol. 2012;36(5):419-26. doi: 10.1159/000343493. Epub 2012 Oct 30. Am J Nephrol. 2012. PMID: 23128049 - A critical role of the podocyte cytoskeleton in the pathogenesis of glomerular proteinuria and autoimmune podocytopathies.
Ye Q, Lan B, Liu H, Persson PB, Lai EY, Mao J. Ye Q, et al. Acta Physiol (Oxf). 2022 Aug;235(4):e13850. doi: 10.1111/apha.13850. Epub 2022 Jun 28. Acta Physiol (Oxf). 2022. PMID: 35716094 Review. - Dynamic (re)organization of the podocyte actin cytoskeleton in the nephrotic syndrome.
Oh J, Reiser J, Mundel P. Oh J, et al. Pediatr Nephrol. 2004 Feb;19(2):130-7. doi: 10.1007/s00467-003-1367-y. Epub 2003 Dec 13. Pediatr Nephrol. 2004. PMID: 14673634 Review.
Cited by
- Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact.
Kiss Z, Elliott S, Jedynasty K, Tesar V, Szegedi J. Kiss Z, et al. Eur J Clin Pharmacol. 2010 Apr;66(4):331-40. doi: 10.1007/s00228-009-0780-y. Epub 2010 Feb 2. Eur J Clin Pharmacol. 2010. PMID: 20127232 Review. - Bariatric surgery and kidney disease outcomes in severely obese youth.
Bjornstad P, Nehus E, van Raalte D. Bjornstad P, et al. Semin Pediatr Surg. 2020 Feb;29(1):150883. doi: 10.1016/j.sempedsurg.2020.150883. Epub 2020 Jan 20. Semin Pediatr Surg. 2020. PMID: 32238288 Free PMC article. Review. - Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus.
Maiese K. Maiese K. Biomed Pharmacother. 2008 Apr-May;62(4):218-32. doi: 10.1016/j.biopha.2008.01.009. Epub 2008 Feb 20. Biomed Pharmacother. 2008. PMID: 18342481 Free PMC article. Review. - Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan.
Tanaka T, Nangaku M, Imai E, Tsubakihara Y, Kamai M, Wada M, Asada S, Akizawa T. Tanaka T, et al. Clin Exp Nephrol. 2019 Feb;23(2):231-243. doi: 10.1007/s10157-018-1632-9. Epub 2018 Sep 4. Clin Exp Nephrol. 2019. PMID: 30182223 Free PMC article. - Kidney-derived c-kit+ progenitor/stem cells contribute to podocyte recovery in a model of acute proteinuria.
Rangel EB, Gomes SA, Kanashiro-Takeuchi R, Saltzman RG, Wei C, Ruiz P, Reiser J, Hare JM. Rangel EB, et al. Sci Rep. 2018 Oct 3;8(1):14723. doi: 10.1038/s41598-018-33082-x. Sci Rep. 2018. PMID: 30283057 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials